Related references
Note: Only part of the references are listed.Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
Inappropriate therapy for methicillin-resistant Staphylococcus aureus:: Resource utilization and cost implications
Andrew F. Shorr et al.
CRITICAL CARE MEDICINE (2008)
Changing epidemiology of invasive candidiasis in intensive care units - Much ado about nothing?
Jack D. Sobel
CRITICAL CARE MEDICINE (2008)
Risk factors for albicans and non-albicans candidemia in the intensive care unit
Jennifer K. Chow et al.
CRITICAL CARE MEDICINE (2008)
Candidemia in nonneutropenic critically ill patients:: Risk factors for non-albicans Candida spp.
E. Geoffrey Playford et al.
CRITICAL CARE MEDICINE (2008)
Treatment-related risk factors for hospital mortality in Candida bloodstream infections
Andrew J. Labelle et al.
CRITICAL CARE MEDICINE (2008)
Secular Trends in Candidemia-Related Hospitalization in the United States, 2000-2005
Marya D. Zilberberg et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2008)
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005:: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing
M. A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Economic implications of an evidence-based sepsis protocol: Can we improve outcomes and lower costs?
Andrew F. Shorr et al.
CRITICAL CARE MEDICINE (2007)
Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study
Kevin W. Garey et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2007)
Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia
Andrew F. Shorr et al.
CRITICAL CARE MEDICINE (2007)
Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia
Mario Tumbarello et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Epidemiology of invasive candidiasis: a persistent public health problem
M. A. Pfaller et al.
CLINICAL MICROBIOLOGY REVIEWS (2007)
Epidemiology of community-onset Candidemia in Connecticut and Maryland
Andre N. Sofair et al.
CLINICAL INFECTIOUS DISEASES (2006)
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study
Kevin W. Garey et al.
CLINICAL INFECTIOUS DISEASES (2006)
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis
TE Zaoutis et al.
CLINICAL INFECTIOUS DISEASES (2005)
Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality
M Morrell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance
J Morgan et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2005)
Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999
WE Trick et al.
CLINICAL INFECTIOUS DISEASES (2002)
Share Paper
